[Pregnancy-specific beta-1 glycoprotein (SP1) as a marker for tumors with or without trophoblastic character]. 1984

A Ruibal, and R Comet, and F J Alvarez Moro, and A Lafuerza, and F M Domenech-Torné, and L Salvador

The pregnancy specific beta-1-glycoprotein (SP1) was measured by radioimmunoassay in 854 persons (control group 103, non-tumoral diseases 212, germinal tumors 30, and non-germinal tumors 509). Amounts higher than 2.5 ng/ml (upper normal limit) were observed in 35 cases with non tumoral diseases (specially chronic liver diseases), 97 of the non-germinal tumors (specially mammary, respiratory and digestive tumors), and 10 of the germinal tumors (pure and mixed choriocarcinomas, and embryonic carcinoma with yolk sac component). SP1 rarely is higher than 5 ng/ml in non-tumoral diseases and non-germinal tumors, while it is higher than 5 ng/ml in germinal tumors. SP1 is a good marker for trophoblastic neoplasms and shows a correlation with HCG-beta.

UI MeSH Term Description Entries
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011257 Pregnancy Proteins Proteins produced by organs of the mother or the PLACENTA during PREGNANCY. These proteins may be pregnancy-specific (present only during pregnancy) or pregnancy-associated (present during pregnancy or under other conditions such as hormone therapy or certain malignancies.) Placental Proteins,Proteins, Placental,Proteins, Pregnancy
D011268 Pregnancy-Specific beta 1-Glycoproteins Glycoproteins with the electrophoretic mobility of BETA-GLOBULINS, secreted by the placental TROPHOBLASTS into the maternal bloodstream during PREGNANCY. They can be detected 18 days after OVULATION and reach 200 mg/ml at the end of pregnancy. They are associated with fetal well-being. Pregnancy-Specific beta 1-Glycoprotein,SP1 Pregnancy Protein,Trophoblast-Specific beta 1-Glycoprotein,beta 1-Glycoprotein, Pregnancy-Specific,beta-1 Glycoprotein, Trophoblast-Specific,PAPP-B,PAPP-C,PSBG-1,Pregnancy Specific beta 1 Glycoprotein,Pregnancy Specific beta-1 Glycoprotein,Pregnancy Specific beta1-Glycoprotein.,Pregnancy-Associated Plasma Protein B,Pregnancy-Associated Plasma Protein C,Pregnancy-Associated beta-Plasma Protein,Pregnancy-Specific beta-1 Globulin,Schwangerschaftsprotein 1,Trophoblastic beta 1-Glycoprotein,Trophoblastic beta(1)-Globulin,Trophoblastic beta-Globulin,beta 1-Globulin, Trophoblast-Specific,1-Glycoproteins, Pregnancy-Specific beta,PAPP B,PSBG 1,Pregnancy Associated Plasma Protein B,Pregnancy Associated Plasma Protein C,Pregnancy Protein, SP1,Pregnancy Specific beta 1 Globulin,Pregnancy Specific beta 1 Glycoproteins,Protein, SP1 Pregnancy,Trophoblast Specific beta 1 Glycoprotein,Trophoblast-Specific beta 1-Globulin,Trophoblast-Specific beta-1 Glycoprotein,Trophoblastic beta Globulin,beta 1 Globulin, Trophoblast Specific,beta 1-Glycoproteins, Pregnancy-Specific,beta-1 Globulin, Pregnancy-Specific,beta-Globulin, Trophoblastic
D004194 Disease A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown. Diseases
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D014328 Trophoblastic Neoplasms Trophoblastic growth, which may be gestational or nongestational in origin. Trophoblastic neoplasia resulting from pregnancy is often described as gestational trophoblastic disease to distinguish it from germ cell tumors which frequently show trophoblastic elements, and from the trophoblastic differentiation which sometimes occurs in a wide variety of epithelial cancers. Gestational trophoblastic growth has several forms, including HYDATIDIFORM MOLE and CHORIOCARCINOMA. (From Holland et al., Cancer Medicine, 3d ed, p1691) Trophoblastic Cancer,Trophoblastic Tumor,Neoplasms, Trophoblastic,Trophoblast Cancer,Trophoblast Neoplasms,Trophoblast Tumor,Cancer, Trophoblast,Cancer, Trophoblastic,Cancers, Trophoblast,Cancers, Trophoblastic,Neoplasm, Trophoblast,Neoplasm, Trophoblastic,Neoplasms, Trophoblast,Trophoblast Cancers,Trophoblast Neoplasm,Trophoblast Tumors,Trophoblastic Cancers,Trophoblastic Neoplasm,Trophoblastic Tumors,Tumor, Trophoblast,Tumor, Trophoblastic,Tumors, Trophoblast,Tumors, Trophoblastic

Related Publications

A Ruibal, and R Comet, and F J Alvarez Moro, and A Lafuerza, and F M Domenech-Torné, and L Salvador
August 1980, Acta pathologica et microbiologica Scandinavica. Section C, Immunology,
A Ruibal, and R Comet, and F J Alvarez Moro, and A Lafuerza, and F M Domenech-Torné, and L Salvador
December 2009, Prenatal diagnosis,
A Ruibal, and R Comet, and F J Alvarez Moro, and A Lafuerza, and F M Domenech-Torné, and L Salvador
August 1986, The Indian journal of medical research,
A Ruibal, and R Comet, and F J Alvarez Moro, and A Lafuerza, and F M Domenech-Torné, and L Salvador
April 1979, Clinical chemistry,
A Ruibal, and R Comet, and F J Alvarez Moro, and A Lafuerza, and F M Domenech-Torné, and L Salvador
January 1980, The Journal of clinical endocrinology and metabolism,
A Ruibal, and R Comet, and F J Alvarez Moro, and A Lafuerza, and F M Domenech-Torné, and L Salvador
May 1982, Clinica chimica acta; international journal of clinical chemistry,
A Ruibal, and R Comet, and F J Alvarez Moro, and A Lafuerza, and F M Domenech-Torné, and L Salvador
July 1982, Journal of reproductive immunology,
A Ruibal, and R Comet, and F J Alvarez Moro, and A Lafuerza, and F M Domenech-Torné, and L Salvador
January 1984, La Ricerca in clinica e in laboratorio,
A Ruibal, and R Comet, and F J Alvarez Moro, and A Lafuerza, and F M Domenech-Torné, and L Salvador
July 1980, Clinical chemistry,
A Ruibal, and R Comet, and F J Alvarez Moro, and A Lafuerza, and F M Domenech-Torné, and L Salvador
January 1987, European neurology,
Copied contents to your clipboard!